Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31016690 | 1.00 | SIGMAR1 (0.51) | SIGMAR1DRD4MCHR1CCR3UBE2M | |
| SCHEMBL27228677 | 0.91 | DPP7 (0.51) | SIGMAR1DRD4DCUN1D1SLC6A12 | |
| SCHEMBL27228675 | 0.90 | SIGMAR1 (0.52) | SIGMAR1MCHR1CCR3UBE2MDCUN1D1 | |
| SCHEMBL31016658 | 0.90 | SIGMAR1 (0.52) | SIGMAR1MCHR1CCR3UBE2MDCUN1D1 | |
| SCHEMBL31016669 | 0.87 | MCHR1 (0.49) | DRD4MCHR1CCR3ACKR3 | |
| SCHEMBL27228329 | 0.87 | MCHR1 (0.49) | DRD4MCHR1CCR3ACKR3 | |
| SCHEMBL31016697 | 0.87 | SIGMAR1 (0.50) | SIGMAR1DRD4MCHR1CCR3 | |
| SCHEMBL27228601 | 0.87 | SIGMAR1 (0.50) | SIGMAR1DRD4MCHR1CCR3 | |
| SCHEMBL27232294 | 0.87 | DRD4 (0.48) | SIGMAR1DRD4MCHR1CCR3MAPK1 | |
| SCHEMBL27228648 | 0.87 | DRD4 (0.48) | SIGMAR1DRD4MCHR1CCR3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | claimed |
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | SIGMAR1 1/4885DRD4 158/4885MCHR1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.